The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

TriSalus, UColorado Anschutz Medical Campus to collaborate on immuno-oncology treatments for liver and pancreatic tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

TriSalus Life Sciences and the University of Colorado Anschutz Medical Campus entered a strategic research collaboration to advance research of immuno-oncology treatments for patients with liver and pancreatic tumors. 

Over the next three years, TriSalus will collaborate with the University of Colorado Anschutz Medical Campus on studies using TriSalus’ proprietary Pressure-Enabled Drug Delivery (PEDD) method for the administration of an investigational toll-like receptor 9 (TLR9) agonist, SD-101.

TriSalus’ platform consists of an investigational immunotherapy, SD-101, that aims to reactivate the immune system within these organs for targeted tumor killing, and the PEDD method, which modulates pressure and flow within blood vessels to improve therapy uptake and tumor response.

CU Innovations has led the establishment of the business relationship while the CU Anschutz research team will focus on creating clinical research to advance TriSalus’ approach.  

Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Northwell invests $1.2M to develop program to treat tumors with noninvasive targeted ultrasound beams

Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
Clinical Roundup

Nivolumab + epigenetic drug induce immune response in some resistant pancreatic cancers

In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account